
    
      This is a randomized, placebo-controlled, triple blinded clinical study to evaluate the
      effects of oral use of "Sekanjebin e Safarjali" (Quince Oxymel) in the Prevention of Migraine
      attacks in patients with simultaneous upper gastrointestinal dysfunction.45 patients with
      Migraine headache aged between 15-70, after taking signed informed consent, according to the
      International headache society criteria for headache [2] are included in this trial. 45 cases
      with Migraine headache with simultaneous upper gastrointestinal dysfunction will allocate to
      three arms by using simple randomization. Quince Oxymel, propranolol and placebo will be
      given as encoded, innominate bottles with the same shape and color. Quince oxymel and placebo
      will be prescribed as 10 cc, three times a day for 4 weeks. Frequency, duration and intensity
      of Migraine Attacks at the beginning time and during 4 weeks of trial, will be evaluated, as
      the primary outcome measures.
    
  